To print: Select File and then Print from your browser's menu

Title: Low-Dose Transdermal Estrogen Has Minimal Effect on Incontinence: Presented at AUGS

"Low-Dose Transdermal Estrogen Has Minimal Effect on Incontinence: Presented at AUGS"

By Paula Moyer SAN DIEGO, CA -- August 6, 2004 -- Low-dose transdermal estrogen does not significantly exacerbate urinary incontinence, according to findings presented here July 31st at the 2004 American Urogynecologic Society/Society of Gynecologic Surgeons Joint Scientific Meeting. "Our findings showed that low-dose estrogen administered by the transdermal route without a progestin has limited or no clinically significant effect on urinary incontinence," said principal investigator L. Elaine Waetjen, MD, assistant professor of obstetrics-gynecology at the University of California in Davis, California. She reported for the Ultra Low-dose Transdermal estRogen Assessment (ULTRA) Study. Previous research had shown that standard-dose oral estrogen combined with progestin worsens urge incontinence in postmenopausal women. Dr. Waetjen and her coinvestigators undertook this study to assess the effect of 2 years of treatment with unopposed ultra low-dose transdermal estradiol on urge incontinence in this population. The ULTRA study, a multicenter, double-blind, randomized, placebo-controlled trial, included 417 postmenopausal women who were taking transdermal estradiol, 0.014 mg per day, for the prevention of osteoporosis. The investigators assessed urinary incontinence episode frequency by type using a validated, self-reported questionnaire at baseline and at several points during the 2-year study. An intention-to-treat ordinal model was used to analyze change in episode frequency and classify women as improved, no significant change, or worsened. Improvement was defined as a decrease in incontinence episodes of 2 or more per day while worsening consisted of an increase of 2 or more episodes per day. The women were an average of 67 ą 5 years old and, at baseline, 42.6% were incontinent. Of these, 39.3% had stress incontinence; 38.7% had urge incontinence, and 22.0% had mixed incontinence. The distribution was similar within the 2 groups, Dr. Waetjen said. After 2 years of estradiol treatment, the odds ratio for worsening urinary incontinence, among those who were already incontinent, was 1.3 (95% CI 0.9-2.0) compared with placebo. The odds ratio of worsening stress incontinence was 1.6 (95% CI 0.9-2.8); for urge incontinence, the risk was 1.0 (95% CI 0.6-1.7). For women who were continent at baseline, the odds ratio for developing incontinence on hormone treatment was 1.21 (95% CI 0.6-2.3). Therefore, during 2 years of treatment, the investigators report that they observed weak evidence for worsening incontinence with the adverse effect on stress incontinence decreasing over time and no effect on urge incontinence. [Presentation title: The Effect of Ultra Low-dose Transdermal Estradiol on Urinary Incontinence (UI) in Postmenopausal Women. Abstract 45]

Copyright Š 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.